VOLUME 65 , ISSUE 3 ( July-September, 2023 ) > List of Articles
Sandeep Nayar, Imaad Rahman, Sunny Kalra, Manish Garg
Keywords : Case report, GM-CSF, Ground glass opacities, Pulmonary alveolar proteinosis
Citation Information : Nayar S, Rahman I, Kalra S, Garg M. Refractory Autoimmune Pulmonary Alveolar Proteinosis Treated with Inhalational GM-CSF: A Case Report. Indian J Chest Dis Allied Sci 2023; 65 (3):160-162.
DOI: 10.5005/jp-journals-11007-0092
License: CC BY-NC 4.0
Published Online: 05-02-2024
Copyright Statement: Copyright © 2023; The Author(s).
Aim and background: Pulmonary alveolar proteinosis is a rare entity with definite evidence to show symptomatic improvement with whole lung lavage therapy. Refractory autoimmune pulmonary alveolar proteinosis continues to be a mystery as upcoming treatment modalities still show variable results. Case description: We hereby present a case of a 40-year-old female who presented with acute severe shortness of breath with a cough for 3–4 days and was a transbronchial biopsy-proven case of pulmonary alveolar proteinosis. On admission to intensive care unit (ICU), the patient was started on inhalational granulocyte–macrophage colony-stimulating factor (GM-CSF). Conclusion: Starting a patient on inhalational GM-CSF provided significant clinical improvement with a decrease in dependence on long-term oxygen therapy thus showing the value of this possible treatment in managing refractory autoimmune pulmonary alveolar proteinosis. Clinical significance: This case highlights the importance of inhalational GM-CSF therapy as a treatment modality for refractory autoimmune pulmonary alveolar proteinosis.
© Jaypee Brothers Medical Publishers (P) LTD.
